In donut hole, Medicare patients don't switch, they stop

When seniors hit the Medicare Part D donut hole, they don't switch to less expensive brands or even cheaper generics, a new Harvard Medical School/CVS Caremark study found. They stop taking meds altogether. Release

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.